Evidence map›Paper›PMID 35614293›Full record

ArticleAdvances in therapy2022

Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.

Antimo Moretti, Sara Liguori, Marco Paoletta, Francesca Gimigliano, Giovanni Iolascon

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Bisphosphonate treatment for secondary osteoporosis in children, youth, and young adults: a systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Orthopaedic Management in Duchenne Muscular Dystrophy.Journal of the Pediatric Orthopaedic Society of North America · 2025
    Review
  7. Article
  8. Current Concepts in the Orthopaedic Management of Duchenne Muscular Dystrophy.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2024
    Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Antimo MorettiDepartment of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", via De Crecchio, 4, 80138, Naples, Italy.
Sara LiguoriDepartment of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", via De Crecchio, 4, 80138, Naples, Italy. sara.liguori@unicampania.it.
Marco PaolettaDepartment of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", via De Crecchio, 4, 80138, Naples, Italy.
Francesca GimiglianoDepartment of Physical and Mental Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Giovanni IolasconDepartment of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", via De Crecchio, 4, 80138, Naples, Italy.
University of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBone loss is a major issue in patients affected by Duchenne muscular dystrophy (DMD), a rare musculoskeletal disorder, particularly in those treated with glucocorticoids (GCs). We aimed to assess the effectiveness of neridronate in terms of bone mineral density (BMD) changes in this population.

methodsWe retrospectively reviewed the records of patients affected by DMD receiving GCs referred to our outpatient from 2015 to 2020. All patients were treated with an intramuscular (IM) injection of neridronate (25 mg every month). Bone density was measured at the lumbar spine (LS; L1-L4 tract) using dual-energy x-ray absorptiometry (DXA) (GE Lunar), no more than 4 weeks before (T0) and after 1 year from neridronate treatment (T1).

resultsEight boys with DMD were included with a mean age at diagnosis of 4.75 ± 2.81 years. Six of them were non-ambulant and two of them had previous low-trauma fractures (a distal femur fracture and a vertebral compression fracture, respectively). All patients were receiving deflazacort [median duration of therapy 11.5 years (interquartile range 2-25)]. At the DXA evaluation (T0), the mean L1-L4 BMD value was 0.716 ± 0.164 g/cm

conclusionsIn this study, we reported for the first time that neridronate may slow bone loss in GC-treated patients with DMD at 1-year follow-up.

Indexed as

Bone Diseases, MetabolicFractures, CompressionMuscular Dystrophy, DuchenneSpinal FracturesAbsorptiometry, PhotonAdolescentAdultBone DensityChildDiphosphonatesGlucocorticoidsHumansMalePilot ProjectsRetrospective StudiesYoung Adult6-amino-1-hydroxyhexane-1,1-diphosphonateDiphosphonatesGlucocorticoidsBone healthDuchenne muscular dystrophyFragility fracturesGlucocorticoidsNeridronate

Identifiers

PMID35614293
PMCPMC9239967
OpenAlexW4281481033

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.